158 related articles for article (PubMed ID: 33657051)
21. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.
Li Y; Kishimoto I; Saito Y; Harada M; Kuwahara K; Izumi T; Takahashi N; Kawakami R; Tanimoto K; Nakagawa Y; Nakanishi M; Adachi Y; Garbers DL; Fukamizu A; Nakao K
Circulation; 2002 Sep; 106(13):1722-8. PubMed ID: 12270869
[TBL] [Abstract][Full Text] [Related]
22. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Paull JR; Widdop RE
J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
[TBL] [Abstract][Full Text] [Related]
23. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Liang B; Leenen FH
J Cardiovasc Pharmacol; 2008 May; 51(5):457-66. PubMed ID: 18418273
[TBL] [Abstract][Full Text] [Related]
24. EndophilinA2 protects against angiotensin II-induced cardiac hypertrophy by inhibiting angiotensin II type 1 receptor trafficking in neonatal rat cardiomyocytes.
Liu Y; Shen HJ; Wang XQ; Liu HQ; Zheng LY; Luo JD
J Cell Biochem; 2018 Nov; 119(10):8290-8303. PubMed ID: 29923351
[TBL] [Abstract][Full Text] [Related]
25. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.
Zhang WW; Bai F; Wang J; Zheng RH; Yang LW; James EA; Zhao ZQ
Drug Des Devel Ther; 2017; 11():3019-3033. PubMed ID: 29081650
[TBL] [Abstract][Full Text] [Related]
26. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.
Haddad GE; Blackwell K; Bikhazi A
Can J Physiol Pharmacol; 2003 Feb; 81(2):142-9. PubMed ID: 12710528
[TBL] [Abstract][Full Text] [Related]
27. Changes in cardiac structure and function in rats immunized by angiotensin type 1 receptor peptides.
Jin Z; Wang J; Zhang W; Zhang G; Jiao X; Zhi J
Acta Biochim Biophys Sin (Shanghai); 2011 Dec; 43(12):970-6. PubMed ID: 22037945
[TBL] [Abstract][Full Text] [Related]
28. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II-induced hypertension and cardiac hypertrophy are differentially mediated by TLR3- and TLR4-dependent pathways.
Singh MV; Cicha MZ; Nunez S; Meyerholz DK; Chapleau MW; Abboud FM
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1027-H1038. PubMed ID: 30793936
[TBL] [Abstract][Full Text] [Related]
30. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects.
Masaki H; Kurihara T; Yamaki A; Inomata N; Nozawa Y; Mori Y; Murasawa S; Kizima K; Maruyama K; Horiuchi M; Dzau VJ; Takahashi H; Iwasaka T; Inada M; Matsubara H
J Clin Invest; 1998 Feb; 101(3):527-35. PubMed ID: 9449684
[TBL] [Abstract][Full Text] [Related]
31. Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease.
Lorell BH
Am J Cardiol; 1999 Jun; 83(12A):48H-52H. PubMed ID: 10750587
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of angiotensin II-induced hypertension and cardiac hypertrophy in transgenic mice overexpressing a type 1 receptor mutant.
Ahmad S; Cesana F; Lamperti E; Gavras H; Yu J
Am J Hypertens; 2009 Dec; 22(12):1320-5. PubMed ID: 19779471
[TBL] [Abstract][Full Text] [Related]
33. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
34. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy.
Suzuki J; Matsubara H; Urakami M; Inada M
Circ Res; 1993 Sep; 73(3):439-47. PubMed ID: 8348688
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension.
Ichihara S; Senbonmatsu T; Price E; Ichiki T; Gaffney FA; Inagami T
Circulation; 2001 Jul; 104(3):346-51. PubMed ID: 11457756
[TBL] [Abstract][Full Text] [Related]
36. Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy.
Vellaichamy E; Zhao D; Somanna N; Pandey KN
Physiol Genomics; 2007 Oct; 31(2):193-202. PubMed ID: 17566078
[TBL] [Abstract][Full Text] [Related]
37. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.
Yamamoto K; Ohishi M; Katsuya T; Ito N; Ikushima M; Kaibe M; Tatara Y; Shiota A; Sugano S; Takeda S; Rakugi H; Ogihara T
Hypertension; 2006 Apr; 47(4):718-26. PubMed ID: 16505206
[TBL] [Abstract][Full Text] [Related]
38. Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
Richer C; Gervais M; Fornes P; Giudicelli JF
J Cardiovasc Pharmacol; 1999 Dec; 34(6):772-81. PubMed ID: 10598119
[TBL] [Abstract][Full Text] [Related]
39. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy.
Zhu YC; Zhu YZ; Gohlke P; Stauss HM; Unger T
Am J Cardiol; 1997 Aug; 80(3A):110A-117A. PubMed ID: 9293963
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
